MLLT10 and acute myeloid leukemia: An investigation involving 18 patients with PICALM-MLLT10 AML revealed that this group demonstrated a higher incidence of extramedullary involvement, an increased occurrence of treatment-related AML, an elevated relapse rate, and an overall survival rate comparable to medium-risk and high-risk subtypes.28